Cargando…

Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma

OBJECTIVE: Currently, treatment of relapsed or refractory multiple myeloma is challenging. Although bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide (VTD-PACE), a potent combination of a proteasome inhibitor, immunomodulatory drug, and conventional chemotherapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Togano, Tomiteru, Andoh, Shohei, Komuro, Masato, Mitsui, Yurika, Itoi, Satoru, Hirai, Risen, Nakamura, Miki, Tanimura, Akira, Sekine, Rieko, Takeshita, Masataka, Miwa, Akiyoshi, Hagiwara, Shotaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751732/
https://www.ncbi.nlm.nih.gov/pubmed/35466165
http://dx.doi.org/10.2169/internalmedicine.9097-21
_version_ 1784850544326606848
author Togano, Tomiteru
Andoh, Shohei
Komuro, Masato
Mitsui, Yurika
Itoi, Satoru
Hirai, Risen
Nakamura, Miki
Tanimura, Akira
Sekine, Rieko
Takeshita, Masataka
Miwa, Akiyoshi
Hagiwara, Shotaro
author_facet Togano, Tomiteru
Andoh, Shohei
Komuro, Masato
Mitsui, Yurika
Itoi, Satoru
Hirai, Risen
Nakamura, Miki
Tanimura, Akira
Sekine, Rieko
Takeshita, Masataka
Miwa, Akiyoshi
Hagiwara, Shotaro
author_sort Togano, Tomiteru
collection PubMed
description OBJECTIVE: Currently, treatment of relapsed or refractory multiple myeloma is challenging. Although bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide (VTD-PACE), a potent combination of a proteasome inhibitor, immunomodulatory drug, and conventional chemotherapeutics, is a widely used regimen, its efficacy and safety are unclear. METHODS: We retrospectively analyzed the clinical data of 35 patients treated with VTD-PACE. RESULTS: The overall response rate was 65.7% (complete response, 5.7%). The median progression-free survival (PFS) and overall survival (OS) were 8.0 [95% confidence interval (CI), 0.9-15.0] and 20.0 (95% CI, 17.5-22.5) months, respectively. Twenty-two (62.9%) patients developed grade 3-4 infections, and no therapy-related deaths occurred. Sixteen of 25 patients (64%) underwent stem cell harvest successfully with more than 2.0×10(6)/kg of CD34 cells after VTD-PACE. Twenty-two patients underwent autologous or allogeneic stem cell transplantation (SCT). The response and survival durations were short in patients without SCT after VTD-PACE [median PFS: 4.0 (95% CI, 2.7-5.3) months; OS: 14.0 (6.9-21.0) months]; however, these responses significantly improved with SCT following VTD-PACE. The PFS was 8.0 (NA) months (p=0.024), and the OS was 21.0 (19.1-22.8) months (p=0.019). CONCLUSION: VTD-PACE is an effective and tolerable salvage regimen and feasible bridging therapy for SCT.
format Online
Article
Text
id pubmed-9751732
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-97517322022-12-22 Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma Togano, Tomiteru Andoh, Shohei Komuro, Masato Mitsui, Yurika Itoi, Satoru Hirai, Risen Nakamura, Miki Tanimura, Akira Sekine, Rieko Takeshita, Masataka Miwa, Akiyoshi Hagiwara, Shotaro Intern Med Original Article OBJECTIVE: Currently, treatment of relapsed or refractory multiple myeloma is challenging. Although bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide (VTD-PACE), a potent combination of a proteasome inhibitor, immunomodulatory drug, and conventional chemotherapeutics, is a widely used regimen, its efficacy and safety are unclear. METHODS: We retrospectively analyzed the clinical data of 35 patients treated with VTD-PACE. RESULTS: The overall response rate was 65.7% (complete response, 5.7%). The median progression-free survival (PFS) and overall survival (OS) were 8.0 [95% confidence interval (CI), 0.9-15.0] and 20.0 (95% CI, 17.5-22.5) months, respectively. Twenty-two (62.9%) patients developed grade 3-4 infections, and no therapy-related deaths occurred. Sixteen of 25 patients (64%) underwent stem cell harvest successfully with more than 2.0×10(6)/kg of CD34 cells after VTD-PACE. Twenty-two patients underwent autologous or allogeneic stem cell transplantation (SCT). The response and survival durations were short in patients without SCT after VTD-PACE [median PFS: 4.0 (95% CI, 2.7-5.3) months; OS: 14.0 (6.9-21.0) months]; however, these responses significantly improved with SCT following VTD-PACE. The PFS was 8.0 (NA) months (p=0.024), and the OS was 21.0 (19.1-22.8) months (p=0.019). CONCLUSION: VTD-PACE is an effective and tolerable salvage regimen and feasible bridging therapy for SCT. The Japanese Society of Internal Medicine 2022-04-23 2022-11-15 /pmc/articles/PMC9751732/ /pubmed/35466165 http://dx.doi.org/10.2169/internalmedicine.9097-21 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Togano, Tomiteru
Andoh, Shohei
Komuro, Masato
Mitsui, Yurika
Itoi, Satoru
Hirai, Risen
Nakamura, Miki
Tanimura, Akira
Sekine, Rieko
Takeshita, Masataka
Miwa, Akiyoshi
Hagiwara, Shotaro
Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma
title Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma
title_full Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma
title_fullStr Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma
title_full_unstemmed Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma
title_short Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma
title_sort bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a salvage and bridging regimen before hematopoietic stem cell transplantation for relapsed or refractory multiple myeloma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751732/
https://www.ncbi.nlm.nih.gov/pubmed/35466165
http://dx.doi.org/10.2169/internalmedicine.9097-21
work_keys_str_mv AT toganotomiteru bortezomibthalidomidedexamethasonecisplatindoxorubicincyclophosphamideetoposideasasalvageandbridgingregimenbeforehematopoieticstemcelltransplantationforrelapsedorrefractorymultiplemyeloma
AT andohshohei bortezomibthalidomidedexamethasonecisplatindoxorubicincyclophosphamideetoposideasasalvageandbridgingregimenbeforehematopoieticstemcelltransplantationforrelapsedorrefractorymultiplemyeloma
AT komuromasato bortezomibthalidomidedexamethasonecisplatindoxorubicincyclophosphamideetoposideasasalvageandbridgingregimenbeforehematopoieticstemcelltransplantationforrelapsedorrefractorymultiplemyeloma
AT mitsuiyurika bortezomibthalidomidedexamethasonecisplatindoxorubicincyclophosphamideetoposideasasalvageandbridgingregimenbeforehematopoieticstemcelltransplantationforrelapsedorrefractorymultiplemyeloma
AT itoisatoru bortezomibthalidomidedexamethasonecisplatindoxorubicincyclophosphamideetoposideasasalvageandbridgingregimenbeforehematopoieticstemcelltransplantationforrelapsedorrefractorymultiplemyeloma
AT hirairisen bortezomibthalidomidedexamethasonecisplatindoxorubicincyclophosphamideetoposideasasalvageandbridgingregimenbeforehematopoieticstemcelltransplantationforrelapsedorrefractorymultiplemyeloma
AT nakamuramiki bortezomibthalidomidedexamethasonecisplatindoxorubicincyclophosphamideetoposideasasalvageandbridgingregimenbeforehematopoieticstemcelltransplantationforrelapsedorrefractorymultiplemyeloma
AT tanimuraakira bortezomibthalidomidedexamethasonecisplatindoxorubicincyclophosphamideetoposideasasalvageandbridgingregimenbeforehematopoieticstemcelltransplantationforrelapsedorrefractorymultiplemyeloma
AT sekinerieko bortezomibthalidomidedexamethasonecisplatindoxorubicincyclophosphamideetoposideasasalvageandbridgingregimenbeforehematopoieticstemcelltransplantationforrelapsedorrefractorymultiplemyeloma
AT takeshitamasataka bortezomibthalidomidedexamethasonecisplatindoxorubicincyclophosphamideetoposideasasalvageandbridgingregimenbeforehematopoieticstemcelltransplantationforrelapsedorrefractorymultiplemyeloma
AT miwaakiyoshi bortezomibthalidomidedexamethasonecisplatindoxorubicincyclophosphamideetoposideasasalvageandbridgingregimenbeforehematopoieticstemcelltransplantationforrelapsedorrefractorymultiplemyeloma
AT hagiwarashotaro bortezomibthalidomidedexamethasonecisplatindoxorubicincyclophosphamideetoposideasasalvageandbridgingregimenbeforehematopoieticstemcelltransplantationforrelapsedorrefractorymultiplemyeloma